Oncology Medical News about myelodysplastic syndromes

Become a Member Today!
Register

Most Viewed Abstracts

1. Report Shows Shift in Starting Salaries for Physicians

2. Recommendations on the use of 18F-FDG PET in oncology

3. Taxane-based combinations as adjuvant chemotherapy of early breast cancer: a meta-analysis of randomized trials

4. Gene expression signatures, clinicopathological features, and individualized therapy in breast cancer

5. Sentinel node biopsy is important in mastectomy for ductal carcinoma in situ

Your Article Summary

See Latest Articles

(Click the title below to leave the MDLinx Network and go to the Journal's Website)

Defining prior therapy in myelodysplastic syndromes and criteria for relapsed and refractory disease - implications for clinical trial design and enrollment
Blood, 07/21/09

Sekeres MA et al. – Clinical trialists designing studies struggle with several important trial design challenges, including which patients constitute the "previously treated" and "relapsed/refractory" MDS populations, and how specifically to define disease "progression". The article considers some of these issues as they relate to study design, including how to identify certain MDS populations and define disease progression.

<< Previous
MSH6 Mutations Arise in Glioblastomas during Temozolomide Therapy...

Next >>
Donor, recipient, and transplant characteristics as risk factors...